Evidence map›Paper›PMID 41809458›Full record

ArticleWorld journal of gastroenterology2026

Pristimerin ameliorates spasmolytic polypeptide-expressing metaplasia by modulating

Jun-Song Wen, Zi-Wei Pan, Xue-Dan Yao, Yan-Qing Liu, Yao-Dong Zhu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in World journal of gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Jun-Song WenDepartment of Integrated Traditional Chinese and Western Medicine Oncology, First Affiliated Hospital of Anhui Medical University, Hefei 230000, Anhui Province, China.
Zi-Wei PanDepartment of Integrated Traditional Chinese and Western Medicine Oncology, First Affiliated Hospital of Anhui Medical University, Hefei 230000, Anhui Province, China.
Xue-Dan YaoDepartment of Integrated Traditional Chinese and Western Medicine Oncology, First Affiliated Hospital of Anhui Medical University, Hefei 230000, Anhui Province, China.
Yan-Qing LiuInstitute of Traditional Chinese Medicine and Western Medicine, School of Medicine, Yangzhou University, Yangzhou 225000, Jiangsu Province, China.
Yao-Dong ZhuDepartment of Integrated Traditional Chinese and Western Medicine Oncology, First Affiliated Hospital of Anhui Medical University, Hefei 230000, Anhui Province, China. zhuyaodong2022@126.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSpasmolytic polypeptide-expressing metaplasia (SPEM) is a gastric precancerous lesion (GPL) with high malignant potential. The ethyl acetate extract of

aimTo investigate the therapeutic effects of pristimerin on SPEM and its underlying mechanisms.

methodsPristimerin was administered to high-dose tamoxifen-induced SPEM mice to assess its effects on pathological progression, glycolytic reprogramming, and

resultsPristimerin effectively ameliorated gastric mucosal damage and oxyntic atrophy induced by high-dose tamoxifen, suppressed the aberrant upregulation of key glycolytic regulators, SPEM-specific markers, and stem cell markers, and upregulated p57 expression. In tamoxifen-induced GES-1 cells, pristimerin exhibited comparable therapeutic effects. Crucially, glycolysis inhibition in GES-1 cells effectively ameliorated tamoxifen-induced SPEM-associated phenotypes. In gastric organoids,

conclusionPristimerin effectively ameliorates gastric mucosal pathological damage and oxyntic atrophy in high-dose tamoxifen-induced SPEM mice, and improves SPEM progression by modulating

Indexed as

Pentacyclic TriterpenesPrecancerous ConditionsStomach NeoplasmsTriterpenesAnimalsCell LineDisease Models, AnimalFemaleGastric MucosaGlycolysisHumansIntercellular Signaling Peptides and ProteinsMaleMetaplasiaMiceOrganoidscelastrolIntercellular Signaling Peptides and ProteinsPentacyclic Triterpenesspasmolytic polypeptideTamoxifenTriterpenesCdkn1cGastric organoidsGastric precancerous lesionGlycolytic reprogrammingPristimerinSpasmolytic polypeptide-expressing metaplasia

Identifiers

PMID41809458
PMCPMC12968642

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.